Pfizer Inc. (NYSE:PFE) Stake Raised by Westhampton Capital LLC

Westhampton Capital LLC raised its holdings in shares of Pfizer Inc. (NYSE:PFE) by 31.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 41,678 shares of the biopharmaceutical company’s stock after acquiring an additional 9,900 shares during the quarter. Westhampton Capital LLC’s holdings in Pfizer were worth $1,206,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Olistico Wealth LLC acquired a new position in Pfizer in the 2nd quarter valued at approximately $25,000. MFA Wealth Advisors LLC acquired a new position in shares of Pfizer in the second quarter worth $29,000. Quarry LP purchased a new stake in shares of Pfizer during the second quarter worth $31,000. Trivant Custom Portfolio Group LLC raised its holdings in shares of Pfizer by 100.0% during the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 600 shares in the last quarter. Finally, Financial Connections Group Inc. purchased a new position in Pfizer in the second quarter valued at about $34,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Trading Down 0.3 %

Shares of NYSE:PFE opened at $28.85 on Wednesday. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $31.54. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86. The company has a market cap of $163.46 billion, a P/E ratio of -62.71, a P/E/G ratio of 1.02 and a beta of 0.67. The stock’s 50-day moving average is $29.07 and its 200-day moving average is $28.48.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The firm had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. During the same quarter last year, the firm posted $0.67 EPS. The company’s revenue was up 2.1% on a year-over-year basis. Equities research analysts predict that Pfizer Inc. will post 2.66 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be paid a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a yield of 5.82%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s payout ratio is currently -365.21%.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on PFE shares. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and raised their price target for the stock from $28.00 to $34.00 in a research note on Wednesday, August 7th. UBS Group raised their price objective on shares of Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research report on Wednesday, July 31st. Wells Fargo & Company boosted their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Finally, StockNews.com upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a report on Wednesday, October 9th. Seven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $33.91.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.